Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0007137,
umls-concept:C0007600,
umls-concept:C0010453,
umls-concept:C0021740,
umls-concept:C0022567,
umls-concept:C0023517,
umls-concept:C0028778,
umls-concept:C0039194,
umls-concept:C0079717,
umls-concept:C0205282,
umls-concept:C0221912,
umls-concept:C0229664,
umls-concept:C0332206,
umls-concept:C0442805,
umls-concept:C0567416,
umls-concept:C1167622,
umls-concept:C1518174,
umls-concept:C1522642
|
pubmed:issue |
1
|
pubmed:dateCreated |
1988-2-4
|
pubmed:abstractText |
Because keratinocytes (KCs) express HLA-DR in a wide variety of skin diseases in which mononuclear leukocytes are observed in close apposition to KCs (i.e., graft-versus-host disease), and since gamma interferon (IFN-gamma) induces HLA-DR expression on KCs, we asked whether IFN-gamma treatment of KCs would influence the adherence of mononuclear leukocytes. When allogeneic peripheral blood mononuclear leukocytes (PBML) and a Leu-3+ T cell clone were coincubated with IFN-gamma-treated KCs (300 U/ml, 3 days), there was a marked increase in binding compared with nontreated KCs. Similar binding results were obtained using a cutaneous squamous carcinoma cell line (SCL-1) after IFN-gamma treatment. The IFN effect was relatively specific for IFN-gamma, as neither IFN-alpha nor -beta had any effect. Tumor necrosis factor exposure (500 U/ml, 3 days) increased the binding of the Leu-3+ T cell clone to both KCs and SCL-1 cells. Neutrophils displayed a less marked (but statistically significant) increase in binding to IFN-gamma-treated KCs. Using the Leu-3+ cell clone and SCL-1 cells, detailed kinetic analysis of the effect of IFN-gamma on binding was performed. The increased adherence between the cells began to appear after only 7 hours of treatment with r-IFN-gamma (300 U/ml) and reached a plateau at 48 hours, with significantly enhanced binding continuing for at least 48 hours after removal of IFN-gamma. The mechanism of binding was explored by preincubation of the PBML/Leu-3+ T cells with anti-LFA-1 (lymphocyte function-associated antigen) antibody (0.6-6.0 micrograms/ml), which totally inhibited the binding with no effect by anti-LFA-2 or -3 or class I or II antibodies despite documented binding of these antibodies to the cells. These results suggest that, after exposure to IFN-gamma, the ability of KCs to bind mononuclear leukocytes is strongly enhanced, and this adherence may be important in leukocyte trafficking in the skin as well as contributing to altered KC-leukocyte interaction, which may be of fundamental importance in a variety of skin disease.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0022-202X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
90
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
17-22
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:2447190-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:2447190-Carcinoma, Squamous Cell,
pubmed-meshheading:2447190-Cell Adhesion,
pubmed-meshheading:2447190-Cells, Cultured,
pubmed-meshheading:2447190-Clone Cells,
pubmed-meshheading:2447190-Epidermis,
pubmed-meshheading:2447190-Humans,
pubmed-meshheading:2447190-Interferon-gamma,
pubmed-meshheading:2447190-Keratins,
pubmed-meshheading:2447190-Leukocytes, Mononuclear,
pubmed-meshheading:2447190-Neutrophils,
pubmed-meshheading:2447190-Recombinant Proteins,
pubmed-meshheading:2447190-Skin Neoplasms,
pubmed-meshheading:2447190-Spectrometry, Fluorescence,
pubmed-meshheading:2447190-T-Lymphocytes
|
pubmed:year |
1988
|
pubmed:articleTitle |
Recombinant gamma interferon increases the binding of peripheral blood mononuclear leukocytes and a Leu-3+ T lymphocyte clone to cultured keratinocytes and to a malignant cutaneous squamous carcinoma cell line that is blocked by antibody against the LFA-1 molecule.
|
pubmed:affiliation |
Department of Pathology, Stanford University School of Medicine, California.
|
pubmed:publicationType |
Journal Article
|